These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34158968)

  • 1. Diabetes mellitus remission in three cats with hypersomatotropism after cabergoline treatment.
    Miceli DD; Vidal PN; Pompili GA; Castillo VA; Soler Arias EA; Niessen SJ
    JFMS Open Rep; 2021; 7(1):20551169211018991. PubMed ID: 34158968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism.
    Miceli DD; García JD; Pompili GA; Rey Amunategui JP; Ferraris S; Pignataro OP; Guitelman M
    J Feline Med Surg; 2022 Dec; 24(12):1238-1244. PubMed ID: 35133181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.
    Scudder CJ; Hazuchova K; Gostelow R; Church DB; Forcada Y; Fowkes RC; Niessen SJ
    J Feline Med Surg; 2021 Feb; 23(2):131-137. PubMed ID: 32684121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment.
    Miceli DD; Zelarayán GS; García JD; Fernández V; Ferraris S
    JFMS Open Rep; 2021; 7(2):20551169211029896. PubMed ID: 34345435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats.
    van Bokhorst KL; Galac S; Kooistra HS; Valtolina C; Fracassi F; Rosenberg D; Meij BP
    J Vet Intern Med; 2021 Mar; 35(2):834-842. PubMed ID: 33621385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.
    Gostelow R; Scudder C; Keyte S; Forcada Y; Fowkes RC; Schmid HA; Church DB; Niessen SJ
    J Vet Intern Med; 2017 Mar; 31(2):355-364. PubMed ID: 28145031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computed tomographic signs of acromegaly in 68 diabetic cats with hypersomatotropism.
    Lamb CR; Ciasca TC; Mantis P; Forcada Y; Potter M; Church DB; Niessen SJ
    J Feline Med Surg; 2014 Feb; 16(2):99-108. PubMed ID: 23847300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life and response to treatment in cats with hypersomatotropism: the owners' point of view.
    Corsini A; Niessen SJ; Miceli DD; Caney S; Zeugswetter FK; Sieber-Ruckstuhl NS; Arenas C; Fleeman LM; Leal RO; Battellino M; Fracassi F
    J Feline Med Surg; 2022 Aug; 24(8):e175-e182. PubMed ID: 35616046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter.
    Niessen SJ; Forcada Y; Mantis P; Lamb CR; Harrington N; Fowkes R; Korbonits M; Smith K; Church DB
    PLoS One; 2015; 10(5):e0127794. PubMed ID: 26023776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased insulin-like growth factor 1 concentrations in a population of non-diabetic cats with overweight/obesity.
    Miceli DD; Jaliquias A; Gallelli MF; García JD; Vecino C; Rey Amunategui JP; Pompili GA; Espiñeira IM; Más J; Pignataro OP
    Domest Anim Endocrinol; 2024 May; 89():106858. PubMed ID: 38830275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersomatotropism and Other Causes of Insulin Resistance in Cats.
    Niessen SJM
    Vet Clin North Am Small Anim Pract; 2023 May; 53(3):691-710. PubMed ID: 36906467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of hypophysectomy for the treatment of hypersomatotropism-induced diabetes mellitus in 68 cats.
    Fenn J; Kenny PJ; Scudder CJ; Hazuchova K; Gostelow R; Fowkes RC; Forcada Y; Church DB; Niessen SJM
    J Vet Intern Med; 2021 Mar; 35(2):823-833. PubMed ID: 33624865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feline Comorbidities: Hypersomatotropism-induced diabetes in cats.
    Scudder C; Church D
    J Feline Med Surg; 2024 Feb; 26(2):1098612X241226690. PubMed ID: 38323402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates in Feline Diabetes Mellitus and Hypersomatotropism.
    Fleeman L; Gostelow R
    Vet Clin North Am Small Anim Pract; 2020 Sep; 50(5):1085-1105. PubMed ID: 32680669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurements of growth hormone and insulin-like growth factor 1 in cats with diabetes mellitus.
    Reusch CE; Kley S; Casella M; Nelson RW; Mol J; Zapf J
    Vet Rec; 2006 Feb; 158(6):195-200. PubMed ID: 16474053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasireotide for the Medical Management of Feline Hypersomatotropism.
    Scudder CJ; Gostelow R; Forcada Y; Schmid HA; Church D; Niessen SJ
    J Vet Intern Med; 2015; 29(4):1074-80. PubMed ID: 25945588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of hypersomatotropism and hyperthyroidism in cats with diabetes mellitus from referral centers in Buenos Aires (2020-2022).
    Miceli DD; García JD; Rey Amunategui JP; Pompili GA; Rial LA; Más J; Molina EM; Pignataro OP
    J Feline Med Surg; 2023 Feb; 25(2):1098612X221148565. PubMed ID: 36779783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment.
    Muschner AC; Varela FV; Hazuchova K; Niessen SJ; Pöppl ÁG
    JFMS Open Rep; 2018; 4(1):2055116918767708. PubMed ID: 29707227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.
    Slingerland LI; Voorhout G; Rijnberk A; Kooistra HS
    Domest Anim Endocrinol; 2008 Nov; 35(4):352-61. PubMed ID: 18801640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersomatotropism and insulin-resistant diabetes mellitus in a cat.
    Morrison SA; Randolph J; Lothrop CD
    J Am Vet Med Assoc; 1989 Jan; 194(1):91-4. PubMed ID: 2914804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.